Evaluation of ramelteon for insomnia in patients with obstructive sleep apnea syndrome.

Evaluation of ramelteon for insomnia in patients with obstructive sleep apnea syndrome. - Evaluation of ramelteon for insomnia in patients with obstructive sleep apnea syndrome.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025514

Enrollment

Registered

2017-01-05

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia in patients with obstructive sleep apnea syndrome.

Interventions

Oral administration of ramelteon (21 days) -&gt

Polysomnography -&gt

Oral administration of placebo (21 days) -&gt

Polysomnography Oral administration of placebo (21 days) -&gt

Polysomnography

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient with insomnia who has 3% ODI(Oxygen Desaturation Index) higher than 40/hr

Exclusion criteria

Exclusion criteria: 1) Patient who already takes a sleeping drug 2) Patient who want to take a sleeping drug immediately

Design outcomes

Primary

Measure	Time frame
Apnea hypopnea index after administration of ramelteon for 3 weeks	—

Secondary

Measure	Time frame
Sleep latency after administration of ramelteon for 3 weeks	—

Countries

Japan

Contacts

Public ContactMakiko Kumamoto

Nara Medical University Second Department of Internal Medicine

mkuma@naramed-u.ac.jp0744-22-3051

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026